View Item 

Show simple item record

Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration
dc.contributor.authorLeung, Samuel C Y
dc.contributor.authorNielsen, Torsten O
dc.contributor.authorZabaglo, Lila A
dc.contributor.authorArun, Indu
dc.contributor.authorBadve, Sunil S
dc.contributor.authorBane, Anita L
dc.contributor.authorBartlett, John M S
dc.contributor.authorBorgquist, Signe
dc.contributor.authorChang, Martin C
dc.contributor.authorDodson, Andrew
dc.contributor.authorEhinger, Anna
dc.contributor.authorFineberg, Susan
dc.contributor.authorFocke, Cornelia M
dc.contributor.authorGao, Dongxia
dc.contributor.authorGown, Allen M
dc.contributor.authorGutierrez, Carolina
dc.contributor.authorHugh, Judith C
dc.contributor.authorKos, Zuzana
dc.contributor.authorLænkholm, Anne‐vibeke
dc.contributor.authorMastropasqua, Mauro G.
dc.contributor.authorMoriya, Takuya
dc.contributor.authorNofech‐mozes, Sharon
dc.contributor.authorOsborne, C Kent
dc.contributor.authorPenault‐llorca, Frédérique M
dc.contributor.authorPiper, Tammy
dc.contributor.authorSakatani, Takashi
dc.contributor.authorSalgado, Roberto
dc.contributor.authorStarczynski, Jane
dc.contributor.authorSugie, Tomoharu
dc.contributor.authorVegt, Bert
dc.contributor.authorViale, Giuseppe
dc.contributor.authorHayes, Daniel F
dc.contributor.authorMcShane, Lisa M
dc.contributor.authorDowsett, Mitch
dc.date.accessioned2019-08-09T17:12:39Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2019-08-09T17:12:39Z
dc.date.issued2019-08
dc.identifier.citationLeung, Samuel C Y; Nielsen, Torsten O; Zabaglo, Lila A; Arun, Indu; Badve, Sunil S; Bane, Anita L; Bartlett, John M S; Borgquist, Signe; Chang, Martin C; Dodson, Andrew; Ehinger, Anna; Fineberg, Susan; Focke, Cornelia M; Gao, Dongxia; Gown, Allen M; Gutierrez, Carolina; Hugh, Judith C; Kos, Zuzana; Lænkholm, Anne‐vibeke ; Mastropasqua, Mauro G.; Moriya, Takuya; Nofech‐mozes, Sharon ; Osborne, C Kent; Penault‐llorca, Frédérique M ; Piper, Tammy; Sakatani, Takashi; Salgado, Roberto; Starczynski, Jane; Sugie, Tomoharu; Vegt, Bert; Viale, Giuseppe; Hayes, Daniel F; McShane, Lisa M; Dowsett, Mitch (2019). "Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration." Histopathology 75(2): 225-235.
dc.identifier.issn0309-0167
dc.identifier.issn1365-2559
dc.identifier.urihttps://hdl.handle.net/2027.42/150497
dc.publisherR Foundation for Statistical Computing
dc.publisherWiley Periodicals, Inc.
dc.subject.otherinterobserver variability
dc.subject.otherpathology
dc.subject.otherscoring protocol
dc.subject.otherKi67
dc.subject.otheranalytical validity
dc.subject.otherimmunohistochemistry
dc.subject.otherinterobserver reproducibility
dc.titleAnalytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMicrobiology and Immunology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/150497/1/his13880.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/150497/2/his13880-sup-0003-DataS1.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/150497/3/his13880_am.pdf
dc.identifier.doi10.1111/his.13880
dc.identifier.sourceHistopathology
dc.identifier.citedreferenceLuporsi E, Andre F, Spyratos F et al. Kiâ 67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res. Treat. 2012; 132; 895 â 915.
dc.identifier.citedreferenceRimm DL, Leung SCY, McShane LM et al. An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. Mod. Pathol. 2019; 32; 59 â 69.
dc.identifier.citedreferenceKoopman T, Buikema HJ, Hollema H, de Bock GH, van der Vegt B. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and interâ platform agreement. Breast Cancer Res. Treat. 2018; 169; 33 â 42.
dc.identifier.citedreferenceStalhammar G, Robertson S, Wedlund L et al. Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer. Histopathology 2018; 72; 974 â 989.
dc.identifier.citedreferenceAcs B, Pelekanou V, Bai Y et al. Ki67 reproducibility using digital image analysis: an interâ platform and interâ operator study. Lab. Invest. 2019; 99; 107 â 117.
dc.identifier.citedreferenceVyberg M, Møller J, Røge R. Nordic immunohistochemical Quality Control â Ki67 assessment. 2018. Available at: http://www.nordiqc.org/epitope.php?xml:id=1. Last accessed 2019â 06â 13.
dc.identifier.citedreferenceR Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2018.
dc.identifier.citedreferenceKirkegaard T, Edwards J, Tovey S et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006; 48; 787 â 794.
dc.identifier.citedreferenceZabaglo L, Salter J, Anderson H et al. Comparative validation of the SP6 antibody to Ki67 in breast cancer. J. Clin. Pathol. 2010; 63; 800 â 804.
dc.identifier.citedreferenceLeung SCY, Nielsen TO, Zabaglo L et al. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer 2016; 2; 16014.
dc.identifier.citedreferenceDenkert C, Budczies J, von Minckwitz G, Wienert S, Loibl S, Klauschen F. Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast 2015; 24 ( Suppl. 2 ); S67 â S72.
dc.identifier.citedreferencede Azambuja E, Cardoso F, de Castro G et al. Kiâ 67 as prognostic marker in early breast cancer: a metaâ analysis of published studies involving 12,155 patients. Br. J. Cancer 2007; 96; 1504 â 1513.
dc.identifier.citedreferenceGerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer 1983; 31; 13 â 20.
dc.identifier.citedreferencePolley MY, Leung SC, Gao D et al. An international study to increase concordance in Ki67 scoring. Mod. Pathol. 2015; 28; 778 â 786.
dc.identifier.citedreferenceEkholm M, Grabau D, Bendahl PO et al. Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines â a Swedish survey with central reâ assessment. Acta Oncol. 2015; 54; 1040 â 1048.
dc.identifier.citedreferenceMengel M, von Wasielewski R, Wiese B, Rudiger T, Mullerâ Hermelink HK, Kreipe H. Interâ laboratory and interâ observer reproducibility of immunohistochemical assessment of the Kiâ 67 labelling index in a large multiâ centre trial. J. Pathol. 2002; 198; 292 â 299.
dc.identifier.citedreferenceFocke CM, Burger H, van Diest PJ et al. Interlaboratory variability of Ki67 staining in breast cancer. Eur. J. Cancer 2017; 84; 219 â 227.
dc.identifier.citedreferenceLaenkholm AV, Grabau D, Moller Talman ML et al. An interâ observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish Breast Cancer Cooperative Group (DBCG). Acta Oncol. 2018; 57; 83 â 89.
dc.identifier.citedreferenceReinert T, Goncalves R, Ellis MJ. Current status of neoadjuvant endocrine therapy in early stage breast cancer. Curr. Treat. Options Oncol. 2018; 19; 23.
dc.identifier.citedreferenceThakur SS, Li H, Chan AMY et al. The use of automated Ki67 analysis to predict Oncotype DX riskâ ofâ recurrence categories in earlyâ stage breast cancer. PLoS ONE 2018; 13; e0188983.
dc.identifier.citedreferenceIwamoto T, Katagiri T, Niikura N et al. Immunohistochemical Ki67 after shortâ term hormone therapy identifies lowâ risk breast cancers as reliably as genomic markers. Oncotarget 2017; 8; 26122 â 26128.
dc.identifier.citedreferencePolley MY, Leung SC, McShane LM et al. An international Ki67 reproducibility study. J. Natl Cancer Inst. 2013; 105; 1897 â 1906.
dc.identifier.citedreferenceEllis MJ, Suman VJ, Hoog J et al. Ki67 Proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J. Clin. Oncol. 2017; 35; 1061 â 1069.
dc.identifier.citedreferenceDowsett M, Smith IE, Ebbs SR et al. Prognostic value of Ki67 expression after shortâ term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst. 2007; 99; 167 â 170.
dc.identifier.citedreferenceXie Y, Chen L, Ma X et al. Prognostic and clinicopathological role of high Kiâ 67 expression in patients with renal cell carcinoma: a systematic review and metaâ analysis. Sci. Rep. 2017; 7; 44281.
dc.identifier.citedreferenceRichardsen E, Andersen S, Alâ Saad S et al. Evaluation of the proliferation marker Kiâ 67 in a large prostatectomy cohort. PLoS ONE 2017; 12; e0186852.
dc.identifier.citedreferenceHe Y, Wang N, Zhou X et al. Prognostic value of Ki67 in BCGâ treated nonâ muscle invasive bladder cancer: a metaâ analysis and systematic review. BMJ Open 2018; 8; e019635.
dc.identifier.citedreferenceDesouki MM, Chamberlain BK, Li Z. The role of immunohistochemistry in the evaluation of gynecologic pathology part 2: a comparative study between two academic institutes. Ann. Diagn. Pathol. 2015; 19; 296 â 300.
dc.identifier.citedreferenceLei Y, Li Z, Qi L et al. The prognostic role of Kiâ 67/MIBâ 1 in upper urinaryâ tract urothelial carcinomas: a systematic review and metaâ analysis. J. Endourol. 2015; 29; 1302 â 1308.
dc.identifier.citedreferenceCohen AL, Factor RE, Mooney K et al. POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen. Breast 2017; 31; 219 â 223.
dc.identifier.citedreferenceCriscitiello C, Disalvatore D, De Laurentiis M et al. High Kiâ 67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and nodeâ positive breast cancer. Breast 2014; 23; 69 â 75.
dc.identifier.citedreferenceRobertson JFR, Dowsett M, Bliss JM et al. Periâ operative aromatase inhibitor treatment in determining or predicting long term outcome in early breast cancer â the POETIC trial. San Antonio Breast Cancer Symposium, 6 December 2017; abstract GS1â 03.
dc.identifier.citedreferencePetrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cutâ off levels of Kiâ 67 in breast cancer: a systematic review and metaâ analysis of 64,196 patients. Breast Cancer Res. Treat. 2015; 153; 477 â 491.
dc.identifier.citedreferenceDowsett M, Nielsen TO, Aâ Hern R et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl Cancer Inst. 2011; 103; 1656 â 1664.
dc.identifier.citedreferenceYerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010; 11; 174 â 183.
dc.identifier.citedreferenceViale G, Regan MM, Mastropasqua MG et al. Predictive value of tumor Kiâ 67 expression in two randomized trials of adjuvant chemoendocrine therapy for nodeâ negative breast cancer. J. Natl Cancer Inst. 2008; 100; 207 â 212.
dc.identifier.citedreferenceViale G, Regan MM, Maiorano E et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1â 98. J. Clin. Oncol. 2007; 25; 3846 â 3852.
dc.identifier.citedreferenceInwald EC, Klinkhammerâ Schalke M, Hofstadter F et al. Kiâ 67 is a prognostic parameter in breast cancer patients: results of a large populationâ based cohort of a cancer registry. Breast Cancer Res. Treat. 2013; 139; 539 â 552.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
his13880.pdf
Size:
1.396MB
Format:
PDF
View/Open
Name:
his13880-sup-0003-DataS1.pdf
Size:
1.633MB
Format:
PDF
View/Open
Name:
his13880_am.pdf
Size:
433.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.